A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
خلاصه خبر
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
تازهترین خبرهای ناشران معتبر را همراه با خلاصه دنبال کنید. برای جزئیات، پیوند منبع اصلی را باز کنید.